Literature DB >> 23163913

Iodine-123 metaiodobenzylguanidine scintigraphy and iodine-123 ioflupane single photon emission computed tomography in Lewy body diseases: complementary or alternative techniques?

Giorgio Treglia1, Ernesto Cason, Pietro Cortelli, Anna Gabellini, Rocco Liguori, Antonio Bagnato, Alessandro Giordano, Giorgio Fagioli.   

Abstract

PURPOSE: To compare myocardial sympathetic imaging using (123)I-Metaiodobenzylguanidine (MIBG) scintigraphy and striatal dopaminergic imaging using (123)I-Ioflupane (FP-CIT) single photon emission computed tomography (SPECT) in patients with suspected Lewy body diseases (LBD).
METHODS: Ninety-nine patients who performed both methods within 2 months for differential diagnosis between Parkinson's disease (PD) and other parkinsonism (n = 68) or between dementia with Lewy bodies (DLB) and other dementia (n = 31) were enrolled. Sensitivity, specificity, accuracy, positive and negative predictive values of both methods were calculated.
RESULTS: For (123) I-MIBG scintigraphy, the overall sensitivity, specificity, accuracy, positive and negative predictive values in LBD were 83%, 79%, 82%, 86%, and 76%, respectively. For (123)I-FP-CIT SPECT, the overall sensitivity, specificity, accuracy, positive and negative predictive values in LBD were 93%, 41%, 73%, 71%, and 80%, respectively. There was a statistically significant difference between these two methods in patients without LBD, but not in patients with LBD.
CONCLUSIONS: LBD usually present both myocardial sympathetic and striatal dopaminergic impairments. (123)I-FP-CIT SPECT presents high sensitivity in the diagnosis of LBD; (123)I-MIBG scintigraphy may have a complementary role in differential diagnosis between PD and other parkinsonism. These scintigraphic methods showed similar diagnostic accuracy in differential diagnosis between DLB and other dementia.
Copyright © 2012 by the American Society of Neuroimaging.

Entities:  

Keywords:  Ioflupane; Lewy body disease; Metaiodobenzylguanidine; Parkinson's disease; dementia with Lewy bodies; nuclear medicine

Mesh:

Substances:

Year:  2012        PMID: 23163913     DOI: 10.1111/j.1552-6569.2012.00774.x

Source DB:  PubMed          Journal:  J Neuroimaging        ISSN: 1051-2284            Impact factor:   2.486


  12 in total

1.  Diagnosis of dementia with Lewy bodies: can 123I-IMP and 123I-MIBG scintigraphy yield new core features?

Authors:  Fumi Sakamoto; Shinya Shiraishi; Noriko Tsuda; Mamoru Hashimoto; Seiji Tomiguchi; Manabu Ikeda; Yasuyuki Yamashita
Journal:  Br J Radiol       Date:  2016-11-29       Impact factor: 3.039

Review 2.  Diagnostic imaging of dementia with Lewy bodies, frontotemporal lobar degeneration, and normal pressure hydrocephalus.

Authors:  Kazunari Ishii
Journal:  Jpn J Radiol       Date:  2019-09-23       Impact factor: 2.374

3.  Do CSF levels of t-Tau, p-Tau and β₁₋₄₂ amyloid correlate with dopaminergic system impairment in patients with a clinical diagnosis of Parkinson disease? A ¹²³I-FP-CIT study in the early stages of the disease.

Authors:  Agostino Chiaravalloti; Alessandro Stefani; Alessandro Fiorentini; Annamaria Lacanfora; Paolo Stanzione; Orazio Schillaci
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-07-10       Impact factor: 9.236

4.  Treatment of dementia with lewy bodies.

Authors:  Brendon P Boot; Eric M McDade; Scott M McGinnis; Bradley F Boeve
Journal:  Curr Treat Options Neurol       Date:  2013-12       Impact factor: 3.598

5.  The Utility of the Combined Use of 123I-FP-CIT and 123I-MIBG Myocardial Scintigraphy in Differentiating Parkinson's Disease from Other Parkinsonian Syndromes.

Authors:  Eiji Matsusue; Yoshio Fujihara; Kenichiro Tanaka; Yuki Aozasa; Manabu Shimoda; Hiroyuki Nakayasu; Kazuhiko Nakamura; Toshihide Ogawa
Journal:  Yonago Acta Med       Date:  2018-06-18       Impact factor: 1.641

6.  Diagnostic accuracy of 123I-meta-iodobenzylguanidine myocardial scintigraphy in dementia with Lewy bodies: a multicenter study.

Authors:  Mitsuhiro Yoshita; Heii Arai; Hiroyuki Arai; Tetsuaki Arai; Takashi Asada; Hiroshige Fujishiro; Haruo Hanyu; Osamu Iizuka; Eizo Iseki; Kenichi Kashihara; Kenji Kosaka; Hirotaka Maruno; Katsuyoshi Mizukami; Yoshikuni Mizuno; Etsuro Mori; Kenichi Nakajima; Hiroyuki Nakamura; Seigo Nakano; Kenji Nakashima; Yoshiyuki Nishio; Satoshi Orimo; Miharu Samuraki; Akira Takahashi; Junichi Taki; Takahiko Tokuda; Katsuya Urakami; Kumiko Utsumi; Kenji Wada; Yukihiko Washimi; Junichi Yamasaki; Shouhei Yamashina; Masahito Yamada
Journal:  PLoS One       Date:  2015-03-20       Impact factor: 3.240

Review 7.  Optimizing Parkinson's disease diagnosis: the role of a dual nuclear imaging algorithm.

Authors:  J William Langston; Jesse C Wiley; Michele Tagliati
Journal:  NPJ Parkinsons Dis       Date:  2018-02-23

8.  123I-ioflupane brain SPECT and 123I-MIBG cardiac planar scintigraphy combined use in uncertain parkinsonian disorders.

Authors:  Susanna Nuvoli; Angela Spanu; Maria Rita Piras; Antonio Nieddu; Aldo Mulas; Gaia Rocchitta; Grazia Galleri; Pier Andrea Serra; Giuseppe Madeddu
Journal:  Medicine (Baltimore)       Date:  2017-05       Impact factor: 1.889

9.  Utility of the combination of DAT SPECT and MIBG myocardial scintigraphy in differentiating dementia with Lewy bodies from Alzheimer's disease.

Authors:  Soichiro Shimizu; Kentaro Hirao; Hidekazu Kanetaka; Nayuta Namioka; Hirokuni Hatanaka; Daisuke Hirose; Raita Fukasawa; Takahiko Umahara; Hirohumi Sakurai; Haruo Hanyu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-08-02       Impact factor: 9.236

10.  Importance of (123)I-ioflupane SPECT and Myocardial MIBG Scintigraphy to Determine the Candidate of Deep Brain Stimulation for Parkinson's Disease.

Authors:  Takashi Asahi; Daina Kashiwazaki; Tatsuya Yoneyama; Kyo Noguchi; Satoshi Kuroda
Journal:  Neurol Med Chir (Tokyo)       Date:  2016-01-20       Impact factor: 1.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.